Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan
The authors treated 16 immunocompetent patients with refractory or relapsed primary CNS lymphoma with topotecan. Fifteen patients had been pretreated with up to three chemotherapy regimens, three of them additionally with whole brain irradiation (WBI), and one with WBI alone. Four complete remission...
Gespeichert in:
| Veröffentlicht in: | Neurology 2004-05, Vol.62 (10), p.1885-1887 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1887 |
|---|---|
| container_issue | 10 |
| container_start_page | 1885 |
| container_title | Neurology |
| container_volume | 62 |
| creator | FISCHER, L THIEL, E KLASEN, H. A KIRCHEN, H JAHNKE, K KORFEL, A |
| description | The authors treated 16 immunocompetent patients with refractory or relapsed primary CNS lymphoma with topotecan. Fifteen patients had been pretreated with up to three chemotherapy regimens, three of them additionally with whole brain irradiation (WBI), and one with WBI alone. Four complete remissions and two partial remissions were achieved. Progression-free survival was 20% at 6 months and 13% at 12 months. |
| doi_str_mv | 10.1212/01.wnl.0000125334.16420.d4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71950584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71950584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-104293b7e9d0e268e040fa5ddf520b3c4726f74fe7e62383ceb34f01589cf40b3</originalsourceid><addsrcrecordid>eNpNkNtKxDAQhoMouq6-ggRB0YvWHHvwTtYjLCoe0LuQTSe40jY16Sr79ma1oGFg5uKbJP-H0D4lKWWUnRCafrV1SuKhTHIuUpoJRtJKrKERlSxLMs5e19GIEFYkvMiLLbQdwnvEJcvLTbRFJZWlJHyE1AOEzrUBsLPYQ627ABV2Ps7Wa9M7v8Sdnzc6dgNt73WNW_CfbhFwWIYeGlwvm-7NNRof3U9uH6fHuHexOteD0e0O2rC6DrA79DF6vrx4mlwn07urm8nZNDGC0j6hRLCSz3IoKwIsK4AIYrWsKisZmXEjcpbZXFjIIWO84AZmXNiYpyiNFZEYo8PfezvvPhYQetXMg4G61i3Ev6qcxryyEBE8_QWNdyHElGqIpyhRK72KUPVyO1V_etWPXnW-Wt4bXlnMGqj-VgefETgYAB2MrqPC1szDPy7PIsr4Nwu8hJU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71950584</pqid></control><display><type>article</type><title>Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>FISCHER, L ; THIEL, E ; KLASEN, H. A ; KIRCHEN, H ; JAHNKE, K ; KORFEL, A</creator><creatorcontrib>FISCHER, L ; THIEL, E ; KLASEN, H. A ; KIRCHEN, H ; JAHNKE, K ; KORFEL, A</creatorcontrib><description>The authors treated 16 immunocompetent patients with refractory or relapsed primary CNS lymphoma with topotecan. Fifteen patients had been pretreated with up to three chemotherapy regimens, three of them additionally with whole brain irradiation (WBI), and one with WBI alone. Four complete remissions and two partial remissions were achieved. Progression-free survival was 20% at 6 months and 13% at 12 months.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/01.wnl.0000125334.16420.d4</identifier><identifier>PMID: 15159503</identifier><identifier>CODEN: NEURAI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adrenal Cortex Hormones - administration & dosage ; Adrenal Cortex Hormones - therapeutic use ; Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Brain Neoplasms - drug therapy ; Brain Neoplasms - radiotherapy ; Combined Modality Therapy ; Cranial Irradiation ; Disease-Free Survival ; Enzyme Inhibitors - therapeutic use ; Female ; Humans ; Lymphoma, Non-Hodgkin - drug therapy ; Lymphoma, Non-Hodgkin - radiotherapy ; Male ; Medical sciences ; Middle Aged ; Neoplasm Proteins - antagonists & inhibitors ; Neurology ; Prospective Studies ; Remission Induction ; Salvage Therapy ; Topoisomerase I Inhibitors ; Topotecan - therapeutic use ; Treatment Outcome</subject><ispartof>Neurology, 2004-05, Vol.62 (10), p.1885-1887</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-104293b7e9d0e268e040fa5ddf520b3c4726f74fe7e62383ceb34f01589cf40b3</citedby><cites>FETCH-LOGICAL-c411t-104293b7e9d0e268e040fa5ddf520b3c4726f74fe7e62383ceb34f01589cf40b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15765152$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15159503$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FISCHER, L</creatorcontrib><creatorcontrib>THIEL, E</creatorcontrib><creatorcontrib>KLASEN, H. A</creatorcontrib><creatorcontrib>KIRCHEN, H</creatorcontrib><creatorcontrib>JAHNKE, K</creatorcontrib><creatorcontrib>KORFEL, A</creatorcontrib><title>Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan</title><title>Neurology</title><addtitle>Neurology</addtitle><description>The authors treated 16 immunocompetent patients with refractory or relapsed primary CNS lymphoma with topotecan. Fifteen patients had been pretreated with up to three chemotherapy regimens, three of them additionally with whole brain irradiation (WBI), and one with WBI alone. Four complete remissions and two partial remissions were achieved. Progression-free survival was 20% at 6 months and 13% at 12 months.</description><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - radiotherapy</subject><subject>Combined Modality Therapy</subject><subject>Cranial Irradiation</subject><subject>Disease-Free Survival</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Lymphoma, Non-Hodgkin - radiotherapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - antagonists & inhibitors</subject><subject>Neurology</subject><subject>Prospective Studies</subject><subject>Remission Induction</subject><subject>Salvage Therapy</subject><subject>Topoisomerase I Inhibitors</subject><subject>Topotecan - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkNtKxDAQhoMouq6-ggRB0YvWHHvwTtYjLCoe0LuQTSe40jY16Sr79ma1oGFg5uKbJP-H0D4lKWWUnRCafrV1SuKhTHIuUpoJRtJKrKERlSxLMs5e19GIEFYkvMiLLbQdwnvEJcvLTbRFJZWlJHyE1AOEzrUBsLPYQ627ABV2Ps7Wa9M7v8Sdnzc6dgNt73WNW_CfbhFwWIYeGlwvm-7NNRof3U9uH6fHuHexOteD0e0O2rC6DrA79DF6vrx4mlwn07urm8nZNDGC0j6hRLCSz3IoKwIsK4AIYrWsKisZmXEjcpbZXFjIIWO84AZmXNiYpyiNFZEYo8PfezvvPhYQetXMg4G61i3Ev6qcxryyEBE8_QWNdyHElGqIpyhRK72KUPVyO1V_etWPXnW-Wt4bXlnMGqj-VgefETgYAB2MrqPC1szDPy7PIsr4Nwu8hJU</recordid><startdate>20040525</startdate><enddate>20040525</enddate><creator>FISCHER, L</creator><creator>THIEL, E</creator><creator>KLASEN, H. A</creator><creator>KIRCHEN, H</creator><creator>JAHNKE, K</creator><creator>KORFEL, A</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040525</creationdate><title>Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan</title><author>FISCHER, L ; THIEL, E ; KLASEN, H. A ; KIRCHEN, H ; JAHNKE, K ; KORFEL, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-104293b7e9d0e268e040fa5ddf520b3c4726f74fe7e62383ceb34f01589cf40b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - radiotherapy</topic><topic>Combined Modality Therapy</topic><topic>Cranial Irradiation</topic><topic>Disease-Free Survival</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Lymphoma, Non-Hodgkin - radiotherapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - antagonists & inhibitors</topic><topic>Neurology</topic><topic>Prospective Studies</topic><topic>Remission Induction</topic><topic>Salvage Therapy</topic><topic>Topoisomerase I Inhibitors</topic><topic>Topotecan - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FISCHER, L</creatorcontrib><creatorcontrib>THIEL, E</creatorcontrib><creatorcontrib>KLASEN, H. A</creatorcontrib><creatorcontrib>KIRCHEN, H</creatorcontrib><creatorcontrib>JAHNKE, K</creatorcontrib><creatorcontrib>KORFEL, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FISCHER, L</au><au>THIEL, E</au><au>KLASEN, H. A</au><au>KIRCHEN, H</au><au>JAHNKE, K</au><au>KORFEL, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2004-05-25</date><risdate>2004</risdate><volume>62</volume><issue>10</issue><spage>1885</spage><epage>1887</epage><pages>1885-1887</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><coden>NEURAI</coden><abstract>The authors treated 16 immunocompetent patients with refractory or relapsed primary CNS lymphoma with topotecan. Fifteen patients had been pretreated with up to three chemotherapy regimens, three of them additionally with whole brain irradiation (WBI), and one with WBI alone. Four complete remissions and two partial remissions were achieved. Progression-free survival was 20% at 6 months and 13% at 12 months.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>15159503</pmid><doi>10.1212/01.wnl.0000125334.16420.d4</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-3878 |
| ispartof | Neurology, 2004-05, Vol.62 (10), p.1885-1887 |
| issn | 0028-3878 1526-632X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71950584 |
| source | MEDLINE; Journals@Ovid Complete; Alma/SFX Local Collection |
| subjects | Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - therapeutic use Adult Aged Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Brain Neoplasms - drug therapy Brain Neoplasms - radiotherapy Combined Modality Therapy Cranial Irradiation Disease-Free Survival Enzyme Inhibitors - therapeutic use Female Humans Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - radiotherapy Male Medical sciences Middle Aged Neoplasm Proteins - antagonists & inhibitors Neurology Prospective Studies Remission Induction Salvage Therapy Topoisomerase I Inhibitors Topotecan - therapeutic use Treatment Outcome |
| title | Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A59%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20of%20relapsed%20or%20refractory%20primary%20central%20nervous%20system%20lymphoma%20(PCNSL)%20to%20topotecan&rft.jtitle=Neurology&rft.au=FISCHER,%20L&rft.date=2004-05-25&rft.volume=62&rft.issue=10&rft.spage=1885&rft.epage=1887&rft.pages=1885-1887&rft.issn=0028-3878&rft.eissn=1526-632X&rft.coden=NEURAI&rft_id=info:doi/10.1212/01.wnl.0000125334.16420.d4&rft_dat=%3Cproquest_cross%3E71950584%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71950584&rft_id=info:pmid/15159503&rfr_iscdi=true |